MediWound Stock (NASDAQ:MDWD)
Previous Close
$18.50
52W Range
$14.14 - $22.50
50D Avg
$17.69
200D Avg
$18.40
Market Cap
$200.58M
Avg Vol (3M)
$104.00K
Beta
0.28
Div Yield
-
MDWD Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NTHI | Neonc Technologies Holdings, Inc. |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. |
| GNFT | Genfit S.A. |
| SLS | SELLAS Life Sciences Group, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| CDXS | Codexis, Inc. |
| TARA | Protara Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| GNLX | Genelux Corporation |
| EPRX | Eupraxia Pharmaceuticals Inc. |